Background and Objectives: During pregnancy, women undergo various physiological and anatomical changes that are accentuated as the pregnancy progresses, but return to their previous state a few weeks/months after the pregnancy. However, a targeted therapeutic approach is needed. Most of the time, during this period, these changes precipitate the appearance of pain, musculoskeletal pain being the most common. Pregnant women should avoid treating musculoskeletal pain with medication and should choose alternative and complementary methods. Exercise along with rest is the basis for treating chronic musculoskeletal pain. Side effects of physical therapy are rare and, in addition, it is not contraindicated in pregnant women. The benefits of this type of treatment in combating pain far outweigh the risks, being an easy way to improve quality of life. The objective of this article is to discuss the management of musculoskeletal pain during pregnancy, to identify the main musculoskeletal pain encountered in pregnant women along with drug treatment, and to expose the beneficial effects of alternative and complementary methods in combating pain. Materials and Methods: A literature search was conducted using medical databases, including PubMed, Google Scholar, and ScienceDirect, using the keywords “changes of pregnancy”, “musculoskeletal pain”, “pregnancy pain”, “pain management”, “pharmacological approach”, “alternative and complementary treatment” and specific sites. Information was collected from studies whose target population included pregnant women who complained of musculoskeletal pain during the 9 months of pregnancy; pregnant women with other pathologies that could increase their pain were not included in this review. Results: The articles related to the most common non-obstetric musculoskeletal pain in pregnancy along with pharmacological treatment options and alternative and complementary methods for musculoskeletal pain management during pregnancy were selected. Conclusions: The results were used to guide information towards the safest methods of therapy but also to raise awareness of the treatment criteria in order to compare the effectiveness of existing methods. Treatment must consider the implications for the mother and fetus, optimizing non-pharmacological therapeutic options.

In cystic fibrosis (CF), the respiratory disease is the main factor that influences the outcome and the prognosis of patients, bacterial infections being responsible for severe exacerbations. The etiology is often multi-microbial and with resistant strains. The aim of this paper is to present current existing antibiotherapy solutions for CF-associated infections in order to offer a reliable support for individual, targeted, and specific treatment. The inclusion criteria were studies about antibiotherapy in CF pediatric patients. Studies involving adult patients or those with only in vitro results were excluded. The information sources were all articles published until December 2021, in PubMed and ScienceDirect. A total of 74 studies were included, with a total number of 26,979 patients aged between 0–18 years. We approached each pathogen individual, with their specific treatment, comparing treatment solutions proposed by different studies. Preservation of lung function is the main goal of therapy in CF, because once parenchyma is lost, it cannot be recovered. Early personalized intervention and prevention of infection with reputable germs is of paramount importance, even if is an asymmetrical challenge. This research received no external funding.

The drug carriers represent a very important and modern pathway used to increase the therapeutic efficacy of the natural active substances. Nano-sized assemblies of noble metals and herbal extracts represent very simple, cheap, biologically and ecologically friendly synthesis. The main aims of this study were to obtain polyurethane nanovesicles containing silver nanoparticles and to evaluate their release rate. The vesicles� sizes, homogeneity and surface charge were studied using a Cordouan Technol. Zetasizer, while the thermal behaviour was assessed by DSC. UV-Vis measurements were done to evaluate the release rate. Toxicological effects were studied by non-invasive techniques on human skin. The results suggest the obtaining of homogenous polyurethane nanovesicles between 80 and 95 nm, with positive surface charge, very good thermal stability and a prolonged release. The non-irritation potential recommends these vesicles as a safe carrier for different herbal extracts.

Study aimed to assess the level of 25-OH-cholecalciferol(vitamin D) and the relation with cholesterol, proteins and glycaemia levels in patients with cystic fibrosis. 58 patients underwent for the annual evaluations and were tested for vitamin D deficiency, as the centre�s protocol requires, besides dosage of cholesterol, glycaemia and proteins levels. Serum levels of 25-hydroxycholecalciferol were compared to levels of cholesterol, proteins and glycaemia, using Pearson correlation and logistic regression. The average value of 25-OH-cholecalciferol was 22,9 ng/mL, suggesting an important deficiency and different stages of 25-OH-cholecalciferol deficiency was found in the majority of patients. Nor a positive correlation neither negative relationship was found between vitamin D and cholesterol (r=0,23), glycaemia or proteins level. Vitamin D levels are not related to cholesterol or proteins in our study. Although cystic fibrosis is characterised by liposoluble vitamins deficiency and lipids impaired digestion, other factors influence the seric levels of vitamin D and lipids.

No abstract